Aetna Offers Members Access to NiteWatch Home Sleep Testing
September 23, 2010
Health care benefits provider Aetna has forged alliance with Swiss Telemedicine provider LifeWatch AG to bring affordable diagnostic service for its patients who are suspected to be suffering from Obstructive Sleep Apnea “OSA”.
The company caters to clients spread across countries including the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. Everyone from high-risk and chronically ill patients to health conscious consumers and wellness programs rely on LifeWatch’s wireless remote telemedicine services. One of the LifeWatch’s most popular services is NiteWatch’s home sleep testing for OSA patients.
Under the partnership with LifeWatch, Aetna will now provide access to the NiteWatch Home Sleep Testing “HST” service for their members effective September 15, 2010.
The partnership comes as a response to the finding that a large percentage of patients with suspected OSA are reluctant to go to a sleep lab to be tested. Since 38 million Americans are affected by OSA1, millions of patients remain undiagnosed and at risk for more serious complications from OSA like stroke and heart disease.
According to LifeWatch, NiteWatch HST is clinically equivalent to sleep lab testing for diagnosing OSA and is conducted in the privacy of the patient’s home making it a less intimidating alternative for many patients and concerned loved ones. For physicians, NiteWatch HST expands patient care options.
“The addition to the NiteWatch service to the Aetna national provider agreement represents an important step in our goal to provide the highest quality diagnostic services at an economical delivery cost. Changing the way healthcare is delivered and serviced is essential to effecting change and allowing high quality clinically superior services to be affordable and available to all. Working with progressive thinkers like Aetna will allow LifeWatch to make a contribution by making affordable home sleep testing services broadly available through all physicians,” Brent Cohen, CEO of LifeWatch, stated.Madhubanti Rudra is a contributing editor for TMCnet. To read more of her articles, please visit her columnist page.
Edited by Stefanie Mosca
Article comments powered by